Bio


Clove Taylor is a PhD candidate in Computational & Systems Immunology at Stanford University School of Medicine. Their work focuses on novel disease endotyping and developing translational approaches to diagnosis and prognostication in critical illness, including sepsis and ARDS.

Lab Affiliations


All Publications


  • Evaluation of a Rapid Immunoassay for Molecular Subphenotype Classification in Pediatric Acute Cardiorespiratory Failure. Critical care medicine Sallee, C. J., Taylor, C. S., Zinter, M. S., Markovic, D., Lim, M. J., Costa Monteiro, A., Cortado, R., Schwingshackl, A., Agus, M., Matthay, M., Sapru, A. 2026; 54 (11): 2977-2983

    Abstract

    Molecular subphenotypes, identified through latent class analysis (LCA) of biomarker profiles, have the potential to guide targeted therapeutics in critical care. We have previously published that intensive insulin management has subphenotype-specific beneficial effects among children with hyperglycemia accompanying cardiorespiratory failure. However, the real-time application of subphenotype-based strategies in clinical settings remains challenging due to the operational aspects of biomarker assays. Our study had three objectives: 1) to compare biomarker measurements from rapid immunoassay and conventional multiplex platforms; 2) to evaluate the cross-platform transportability of a conventional assay-based parsimonious classifier for LCA-derived subphenotypes and compare it with a classifier trained directly on rapid immunoassay data; and 3) to assess the prognostic and predictive significance of rapid immunoassay-based subphenotypes.Retrospective cohort study.Multicenter PICUs.Two hundred sixty-nine critically ill children with acute cardiorespiratory failure and hyperglycemia (2012-2016).None.LCA was previously used to derive hyperinflammatory and hypoinflammatory classes using a conventional multiplex assay of 13 plasma biomarkers. After feature selection, a parsimonious classifier using interleukin (IL)-6, IL-8, and soluble tumor necrosis factor receptor 1 (sTNFR-1) was developed to predict LCA-derived subphenotypes. We applied this classifier to rapid immunoassay biomarker measurements, yielding an area under the receiver operating characteristic curve (AUROC) of 0.90 (95% CI, 0.85-0.95). However, calibration was poor due to systematic underestimation of sTNFR-1 concentrations by the rapid platform. We then derived and internally validated via bootstrapping a de novo classifier using rapid immunoassay data, achieving an AUROC of 0.90 (95% CI, 0.86-0.95) and excellent calibration. Using a probability threshold of ≥ 0.5, the de novo classifier matched LCA-derived classifications in 241 of 269 cases (accuracy 89.6%). Rapid immunoassay-based subphenotypes demonstrated differences in mortality (33.3% in hyperinflammatory vs. 11.8% in hypoinflammatory; p = 0.009) and differential response to intensive insulin management (interaction p = 0.024).A parsimonious, rapid immunoassay-based classifier can approximate LCA-derived molecular subphenotypes while preserving their prognostic and predictive significance, with the potential to inform future subphenotype-based precision trials.

    View details for DOI 10.1097/CCM.0000000000007339

    View details for PubMedID 42704284

  • C6 peptide blockade of Hv1 channels inhibits neutrophil migration into the lungs to suppress Pseudomonas aeruginosa-induced acute lung injury. Respiratory research Zhao, R., Lopez, B., Majumder, N., Kasparian, A., Hua, P., Dai, H., Nayak, M., Zyrianova, T., Taylor, C., Ding, Y., Sallee, C. J., Sapru, A., Goldstein, S. A., Schwingshackl, A. 2025; 26 (1): 339

    Abstract

    BACKGROUND: Acute Lung Injury (ALI) and its most severe form, Acute Respiratory Distress Syndrome (ARDS), are critical pulmonary conditions characterized by life-threatening acute hypoxic respiratory failure, affecting over three million individuals globally each year. ALI involves alveolar inflammation and disruption of the alveolar-capillary barrier, primarily driven by neutrophil infiltration and the release of inflammatory mediators. In our previous study using a lipopolysaccharide (LPS)-induced mouse model of ALI, we demonstrated that C6, a peptide inhibitor of voltage-gated proton channels (Hv1), ameliorates lung injury, identifying Hv1 as a potential therapeutic target. However, (i) whether the anti-inflammatory effects of C6 are translatable to a clinically relevant live bacterial infection model, and (ii) the molecular mechanisms underlying these anti-inflammatory effects, remain unknown, and are a crucial next step towards targeted rational drug development. METHODS: To induce ALI, we used an intratracheal Pseudomonas aeruginosa infection model, a gram-negative bacterium relevant in ventilated and immunocompromised patients. A separate group of infected mice also received intravenous treatment with C6 (4 mg/kg). Lung injury severity was evaluated using histopathological analysis. Bronchoalveolar lavage (BAL) fluid was collected to quantify neutrophil infiltration and proinflammatory cytokines concentrations. In addition, reactive oxygen species (ROS) production and intracellular calcium levels in BAL neutrophils were measured. RNA sequencing of BAL neutrophils was conducted to assess C6-induced transcriptional changes. Key findings were validated in vitro using human neutrophils. RESULTS: C6 mitigates P. aeruginosa-induced ALI in mice by reducing neutrophil infiltration into the alveolar space by ~ 86%, improving lung injury scores, decreasing BAL fluid proinflammatory cytokine levels, and suppressing neutrophil ROS production and intracellular calcium levels. RNA sequencing of BAL neutrophils revealed 51 downregulated genes, including key regulators of neutrophil migration, cytokine release, and ROS production; only three genes were upregulated and they also have roles in neutrophil immune defense. In human neutrophils, C6 similarly inhibited chemotaxis and reduced ROS and cytokine release, and calcium influx. CONCLUSIONS: Targeting Hv1 with C6 effectively protects against P. aeruginosa-induced ALI by limiting neutrophil recruitment and activation. These findings establish C6 as a promising therapeutic candidate against infectious ALI and provide important mechanistic insights into its immunomodulatory effects on neutrophils.

    View details for DOI 10.1186/s12931-025-03409-0

    View details for PubMedID 41316271

    View details for PubMedCentralID PMC12661846

  • Circulating endothelial signatures correlate with worse outcomes in COVID-19, respiratory failure and ARDS. Critical care (London, England) Costa Monteiro, A. C., Pickering, H., Sarma, A., Taylor, C. S., Jenkins, M. M., Hsu, F. M., Nadel, B., Levy, O., Baden, L. R., Melamed, E., Ehrlich, L. I., McComsey, G. A., Sekaly, R. P., Cairns, C. B., Haddad, E. K., Shaw, A. C., Hafler, D. A., Montgomery, R. R., Corry, D. B., Kheradmand, F., Atkinson, M. A., Brakenridge, S. C., Higuita, N. I., Metcalf, J. P., Hough, C. L., Messer, W. B., Pulendran, B., Nadeau, K. C., Davis, M. M., Geng, L. N., Fernandez-Sesma, A., Simon, V., Krammer, F., Kraft, M., Bime, C., Calfee, C. S., Erle, D. J., Bosinger, S., Eckalbar, W., Maecker, H., Rahman, A., Guan, L., Peters, B., Kleinstein, S. H., Augustine, A. D., Diray-Arce, J., Becker, P. M., Rouphael, N., Agus, M., Kulkarni, H., Schaenmann, J. M., Salehi-Rad, R., Matthay, M. A., Reed, E. F., Sapru, A. 2025; 29 (1): 432

    Abstract

    Elevated circulating endothelial cells (CECs), released from monolayers after insult, have been implicated in worse outcomes in ARDS and COVID-19, however there is no consensus proteomic phenotype that define CECs. We queried whether a transcriptomic approach would alternatively support the presence of endothelial cells in circulation and correlate with worsening respiratory failure.To test whether elevated endothelial cell signatures (ECS) in circulation plays a role in worse respiratory outcomes, we used unsupervised bulk-transcriptome deconvolution to quantify ECS% in two cohorts. Our pilot analysis included pediatric patients requiring invasive mechanical ventilation (CAF-PINT, NCT01892969). Our validation cohort included adult hospitalized patients with COVID-19 (IMPACC, NCT04378777), testing the association of ECS% to outcomes in patients at risk of acute respiratory failure/ARDS. Primary outcome was 28-day mortality.In CAF-PINT, day 0 ECS% was higher in non-survivors compared to survivors of respiratory failure (2.8%, IQR 2.4-3.4% versus 2.6%, IQR 2.2-3.0% n = 244, p < 0.05, Wilcoxon rank-sum). In IMPACC, baseline ECS% (< 72 h of hospitalization) was higher in COVID-19 non-survivors versus survivors (2.9%, IQR 2.6-3.4%, versus 2.7%, IQR 2.3-3.1%, n = 932, p < 0.001, Wilcoxon rank-sum). Each 1% increase in baseline ECS% was significantly associated with mortality (adjusted OR 1.36, CI 1.03-1.79) by multivariable logistic regression. Increased baseline ECS% was associated with worse respiratory trajectories (2.5%, IQR 2.2-2.8% for trajectory with no oxygen requirements, 2.9%, IQR 2.6-3.4% for the trajectory with fatal outcome by day 28, n = 932, p < 0.001, one-way ANOVA).Quantifying ECS by deconvolution supports a transcriptomics-driven approach towards the non-invasive evaluation of endothelial damage in respiratory outcomes. This is a first step towards elucidating mechanistic components linking endothelial damage to ARDS utilizing non-invasive, circulating transcriptomic data by leveraging a novel deconvolution approach.

    View details for DOI 10.1186/s13054-025-05596-0

    View details for PubMedID 41088445

    View details for PubMedCentralID PMC12522733

  • Biologic Mechanisms Underlying the Heterogeneous Response to Tight Glycemic Control among Differentially Inflamed Patients in the HALF-PINT Trial AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE Zinter, M. S., Taylor, C. S., Markovic, D., Pellegrini, M., Wong, K., Balliu, B., Gala, K. P., Asaro, L. A., Nadkarni, V. M., McQuillen, P. S., Vangala, S. S., Sinha, P., Matthay, M. A., Agus, M. S. D., Sapru, A., CAF PINT Investigators PALISI Network 2025; 211 (8): 1463-1473

    Abstract

    Rationale: Tight glycemic control (TGC) with insulin has not consistently shown benefit in critically ill patients. We previously reported that the subset of children with a hyperinflammatory subphenotype benefited from TGC in the HALF-PINT (Heart and Lung Failure - Pediatric Insulin Titration) study of hyperglycemic children with heart and lung failure and the IIT-SBPP (Intensive Insulin Treatment - Severely Burned Pediatric Patients) study in severely burned pediatric patients. However, whether this effect was mediated through a reduction in inflammation or some other biologic process is not fully understood. Objectives: To deepen the understanding of inflammatory subphenotypes and explore the biologic mechanisms underlying heterogeneous response to TGC. Methods: Plasma cytokine measurements and whole-blood transcriptomics from 740 blood samples collected on Pre- and Post-treatment Study Days 0, 2, and 4 from 293 HALF-PINT participants (n = 250 hypoinflammatory and n = 43 hyperinflammatory) were used to identify cytokine and gene expression signatures of differential responses to TGC. Measurements and Results: Patients with the hyperinflammatory subphenotype had greater baseline expression of genes relating to inflammation, cell-cycle activity, and immunometabolism. Hyperinflammatory patients treated to a target glucose range of 80-110 mg/dl experienced greater reductions in inflammatory cytokines, innate immune gene expression, and heme metabolism gene expression, as well as an increase in lymphocyte gene expression, compared with those treated to a target range of 150-180 mg/dl. Causal mediation testing indicated that these changes partly explained the observed mortality benefit of TGC in the hyperinflammatory subgroup of patients. Conclusions: These findings expand our understanding of the biology underlying inflammatory subphenotypes and provide biologic insight into the mortality benefit of TGC in hyperinflammatory children.

    View details for DOI 10.1164/rccm.202409-1719OC

    View details for Web of Science ID 001578061300023

    View details for PubMedID 40493436

    View details for PubMedCentralID PMC12318495